Improving outcomes in pediatric procedural sedation.

Improving outcomes in pediatric procedural sedation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Improving outcomes in pediatric procedural sedation. Abstract Text:

BACKGROUND: In Fall 2003, Chris Evert Children's Hospital (CECH; Fort Lauderdale, Florida) exclusively used chloral hydrate for moderate sedation. As procedures became longer and more complex, pentobarbital became the primary sedative used. Yet children receiving pentobarbital were awakening during the procedure from paradoxical drug reactions or insufficient sedation. In 2003, the failed sedation rate was 12.29%--more than six times the national benchmark of 2%. METHODS: The pediatric sedation team created a pediatric sedation protocol, which reflected the designation of an a2-adrenergic agonist, dexmedetomidine (dex), as the drug of choice and spearheaded a variety of performance improvement changes, including creation of a stand-alone eight-bed sedation unit to accommodate the registration process and pre-assessment and postprocedure monitoring and to include the parent in the treatment continuum. RESULTS: Following the implementation of the new protocol in 2003, the failed sedation rate for children undergoing various diagnostic and therapeutic procedures decreased from 12.29% to 1.63% in 2004, 0.19% in 2005, and 0.28% in 2006; in 2007 the rate was 0.72%--reflecting an average 98% reduction in the failed sedation rate. DISCUSSION: The continued improvement and success in pediatric sedation over time indicates that the protocol has sustained benefits and lasting value.

Improving outcomes in pediatric procedural sedation. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Improving outcomes in pediatric procedural sedation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Joint Commission journal on quality and patient sa

VOLUME: 34

Page Numbers: 192-5

Journal Abbreviation:

ISSN: 1553-7250

DAY: 12

MONTH: Apr

YEAR: 2008

Improving outcomes in pediatric procedural sedation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101238023

Improving outcomes in pediatric procedural sedation. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Improving outcomes in pediatric procedural sedation. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Improving outcomes in pediatric procedural sedation.

AFFILIATION: Chris Evert Children's Hospital, Fort Lauderdale, Florida, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Jt Comm J Qual Patient Saf

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Improving outcomes in pediatric procedural sedation Related Publications

• Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety.
• Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
• Comparison of RRR-alpha- and all-rac-alpha-tocopherol uptake by permanent rat skeletal muscle myoblasts (L6 cells): effects of exogenous lipoprotein lipase.
• Connection piece for hearing device support hook.
• Decreasing asthmagens in hospitals.
• Dynamic effects on j-couplings across hydrogen bonds in proteins.
• Improving outcomes in pediatric procedural sedation.
• Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate.
• Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.
• New Abietane Diterpenoids from the Mangrove Avicennia marina.
• New report on decreasing asthmagens in hospitals.
• Our bodies and the legacy of "better living through chemistry.
• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
• Reliability of maximal voluntary muscle strength and power testing in older men.
• Results of alloarthroplasty of the hip joint.
• Site-specific variations of carbonyl chemical shift anisotropies in proteins.
• Structure and functional analysis of the MYND domain.
• Structure, derivatization, and antitumor activity of new griseusins from Nocardiopsis sp.
• Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
• The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
• [Demonstration of I/i- and Pr-antigens on lymphocytes by cold agglutinins (proceedings)]
• [Esophagus carcinoma in young adults.]
• [Experiences with a barbituric acid-free hypnotic combination.]
• [Not Available.]